Trials / Terminated
TerminatedNCT01760616
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
A Prospective, Multicenter, Open-labeled, Parallel -Controlled Clinical Study Investigating Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 790 (actual)
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.
Detailed description
A Prospective, Multicenter, Open-labeled, Parallel -controlled Clinical Study, to evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Huaier Granule | Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd.. |
Timeline
- Start date
- 2011-11-07
- Primary completion
- 2015-08-15
- Completion
- 2017-06-30
- First posted
- 2013-01-04
- Last updated
- 2020-03-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01760616. Inclusion in this directory is not an endorsement.